Search Bar & Filters
Found 3 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the clinical effectiveness and safety of icotrokinra in adults with moderately to severely active Crohns disease, a long-term condition causing serious inflammation in the intestines. The study is a Phase 2b3 randomized, double-blind, placebo-controlled trial aiming to better understand how well icotrokinra works in treating this condition. Participants will receive one of several oral treatments daily during an initial 12-week induction phase either one of two doses of icotrokinra or a matching placebo. After Week 12, their response status will guide further treatment. Those responding to icotrokinra may be randomized to maintenance doses for up to 40 weeks, with some eligible to join a long-term extension study. Placebo recipients who respond may continue placebo or switch to icotrokinra under specific conditions. Throughout the trial, participants will undergo regular assessments to monitor clinical response, remission, and endoscopic healing at Weeks 12 and 40. Safety will be closely followed up to four weeks after the last dose. The study measures various outcomes including patient-reported remission, inflammatory markers, quality of life, and fatigue. Total participation may extend up to several months depending on treatment phase and eligibility for long-term follow-up.
Actively Recruiting
Extension Study of ADX-324 Investigating Long-Term Dosing in Participants With Hereditary Angioedema
This research aims to further understand the safety and effectiveness of additional doses of ADX-324 in people with Type I and Type II hereditary angioedema HAE. It is an extension of the Phase 3 ADX-324-301 trial and focuses on participants who have completed that earlier study. The trial also examines how the drug behaves in the body and its impact on quality of life. Participants in this study receive one of two dosage levels of ADX-324, a small interfering RNA siRNA duplex oligonucleotide. The study does not involve random assignment, and both participants and researchers are unaware of which dose is given. This extension study continues dosing and monitoring after the initial Phase 3 trial, focusing on long-term treatment. During the trial, participants will be regularly assessed for safety and how well ADX-324 prevents HAE attacks over 36 months. Researchers will collect pharmacodynamic and pharmacokinetic data, as well as quality of life information. The study is sponsored by ADARx Pharmaceuticals, Inc., and involves ongoing monitoring to understand the effects of prolonged ADX-324 treatment.
Actively Recruiting
Researchers are evaluating the efficacy and safety of ADX-324 in adults with Type 1 or Type 2 hereditary angioedema HAE. This Phase 3 clinical trial aims to study how well ADX-324 prevents HAE attacks while also assessing its safety, how the body processes the drug, how it affects disease activity, and quality of life for participants. The sponsor leading this research is ADARx Pharmaceuticals, Inc. Participants will be randomly assigned to one of three groups two different dose levels of ADX-324 or a placebo. The study uses a parallel design where participants receive their assigned treatment over a set period. The investigational drug, ADX-324, is a small interfering RNA siRNA duplex oligonucleotide designed to target prekallikrein. Treatment is administered under double-blind conditions so neither participants nor study staff know which treatment is given. During the study, participants will be monitored for the number and severity of HAE attacks from Day 22 to Week 25. Researchers will also evaluate the quality and pattern of these attacks and collect health-related quality of life information. Safety assessments and pharmacokinetic and pharmacodynamic studies will be conducted throughout. The total duration for participant involvement extends through the treatment period ending around Week 25, with ongoing monitoring by the study team.